RT Journal Article
SR Electronic
T1 Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2883
VO 40
IS Suppl 56
A1 Robert Mroz
A1 Agnieszka Tycinska
A1 Pawel Lisowski
A1 Joanna Bierla
A1 Lukasz Minarowski
A1 Robert Milewski
A1 Anna Lisowska
A1 Piotr Boros
A1 Elzbieta Chyczewska
A1 William MacNee
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P2883.abstract
AB We have performed a parallel group study to compare the effects of Atorvastatin 40mg once daily for 3 months (n=13) or placebo (n=5) as an add-on treatment to Formoterol therapy in 18 patients with mild to moderate COPD (mean FEV1% predicted 59.58±SD 20.43 and 50.4±SD 11.55 for study group and control respectively). Fiberoptic bronchoscopy and transbronchial lung biopsy (TBB) was carried out at baseline and after 3 months of treatment. Twelve subjects, (11 male, 1 female, mean age 64.58 ± SD 7.03 and Control: 5 males, mean age 68.4± SD 6.5 completed the study. TBB specimens were processed for: microarrays and immunohistochemistry. Patients had spirometry, lung volumes, SGRQ, 6MWD, serum lipids and hs-CRP measured before and after treatment. Results: After therapy symptoms measured by SGRQ and 6MWD significantly improved within study group. There was no significant change in FEV1 nor lung volumes. In TBB there was a significant decrease in inflammatory cells numbers (CD45+ cells decreased from 62,51 to 27.01% before and after treatment within study group (p=0,008) and in comparison to placebo 27.01 vs 50,05 (p=0,002). Gene expression profiling revealed over 600 genes that met the criteria for differential expression (logFC&gt;0.05, p&lt;0.05). Atorvastatin therapy had a significant impact on gene expression in lung tissue of atorvastatin treated patients, mainly by downregulation of genes involved in inflammatory pathways. These data indicate that atorvastatin may have potential beneficial effects in COPD patients through an anti-inflammatory mechanism.